The related Retatrutide Benefits page explores that topic in more detail
Cardiovascular and Heart Health Benefits Beyond Weight Loss The LEADER, SUSTAIN-6, and SELECT trials documented that GLP-1 medications reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 2635% in patients with existing heart disease or high cardiovascular risk
Two-thirds of participants achieved a BMI below 30, and one-third reached a BMI below 25, starting from a mean baseline BMI of 40
These represent savings of 60 to 85 percent compared to brand name pricing
a generic reconstitution guide cannot make that product-specific choice. How is contamination risk reduced during reconstitution
These results translated to significant proportions of participants achieving clinically meaningful weight loss: 5% or More Weight Reduction: 92% (4 mg), 100% (8 mg), 100% (12 mg), and 27% (placebo) 10% or More Weight Reduction: 75% (4 mg), 91% (8 mg), 93% (12 mg), and 9% (placebo) 15% or More Weight Reduction: 60% (4 mg), 75% (8 mg), 83% (12 mg), and 2% (placebo) These data underscore retatrutides potential to deliver unprecedented weight loss in a significant portion of individuals with obesity
